Sugar-based Excipients Market Revenue, Demand, Opportunity, Segment and Key Trends

The Increasing use of co-processed excipients to improve the dissolution, bioavailability, and solubility of recently developed active pharmaceutical ingredients (APIs), rapid growth in the generics market due to the patent expiration of many blockbuster drugs, and increasing development of orally disintegrating tablets (ODTs) are expected to propel the growth of this market. However, stringent regulatory requirements leading to shortage of FDA-approved manufacturing sites can hinder their market growth to a certain extent.

The report “Sugar-Based Excipients Market by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), Type (Powder/Granule, Crystal, Syrup), Functionality (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, Parenteral) – Global Forecast”, the sugar excipients market has witnessed healthy growth during the last decade, and is expected to grow at a CAGR of 4.3%, to reach USD 1,060.6 Million.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=242342136

Sugar-Based Excipients Market Segmentation in Detailed:

Based on type, segmented into powders/granules, direct compression sugars, crystals, and syrups.

on the basis of functionality, segmented into fillers & diluents, flavoring agents, tonicity agents, and other functionalities.

Based on formulation, segmented into oral formulations, parenteral formulations, topical formulations, and other formulations.

Based on the type, segmented into powders/granules, direct compression sugars, crystals, and syrups. Similarly, on the basis of functionality, the market is segmented into fillers & diluents, flavoring agents, tonicity agents, and other functionalities

The actual sugar accounted for the largest share of the global sugar excipients market. The sugar alcohols segment is expected to witness the highest growth in the next five years primarily due to the rising use of mannitol in a wide range of dosage forms such as oral and topical, and its high adaptability in emerging formulation technologies, such as orally disintegrating tablets. On the basis of type, powders/granules segment accounted for the large share of the global Sugar-Based Excipients Market. The large share of the powders/granules segment is mainly attributed to its wide use in various types of formulations in the pharmaceutical industry.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242342136

Geographical View in-detailed:

Europe is the largest regional segment for the global sugar excipients market. The large share of this regional segment can be attributed to increasing investments in drug development, increasing production of generic drugs, and favorable government initiatives in the region. The market in the Asia-Pacific region is expected to register the highest CAGR owing to the significant growth in the regional healthcare market as well as the pharmaceutical industry, growing scientific base and capability, and favorable government policies, and low-cost manufacturing advantage in this region.

Global Key Leaders:

Roquette Group (France), DFE Pharma (Germany), BASF SE (Germany), and Ashland Inc. (U.S.), held the major share of the sugar excipients market, and are expected to dominate the market during the forecast period. Other major players in this market are Associated British Foods Plc (U.K.), Cargill, Inc. (U.S.), Colorcon, Inc. (U.S.), FMC Corporation (U.S.), MEGGLE AG (Germany), and The Lubrizol Corporation (U.S.).

Global Molecular Cytogenetics Market 2020: Developments, Challenges, and Forecast Report

[147 Pages Report] The Molecular Cytogenetics Market is projected to reach $2.52 Billion, at a CAGR of 10.1%

The report “Molecular Cytogenetics Market by Product (Kit, Reagent, Probe, Consumable, Software, Service), Technique (In-Situ, FISH, Comparative Genomic Hybridization), Application (Cancer, Genetic), End User (Research Labs, Institutes) – Forecast”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the market along with the estimates and forecasts of the revenue and market share analysis.

Targeted therapies differ from standard chemotherapy in several ways. These therapies act on specific molecular targets associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells. In solid tumors, significantly high levels of chromosome abnormalities have been detected, but distinction between critical and irrelevant events has been a major challenge. The emergence of molecular-based cytogenetic techniques such as fluorescence in situ hybridization is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer prevention, diagnosis, prognosis, and therapy selection, alone or in combination with other diagnostic methods. The increasing use for molecular cytogenetics in clinical oncology will drive the growth of the global market.

Browse 78 market data tables and 47 figures spread through 147 pages and in-depth TOC – Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=148469224

Market Segmentation in Detailed:

On the basis of techniques, the molecular cytogenetics market is segmented into comparative genomic hybridization, fluorescence in situ hybridization, in situ hybridization, and other techniques.

Based on applications, the market is segmented into genetic disorders, cancer, personalized medicine, and other applications. The genetic disorders segment is expected to account for the largest share of the global market.

Based on end users, the molecular cytogenetics market is segmented into clinical and research laboratories, academic research institutes, pharmaceutical and biotechnology companies, and others. The clinical and research laboratories segment is expected to account for the largest share of the global market. Rise in healthcare expenditure has resulted in the increasing diagnosis of genetic disorder and cancer resulting in increasing use of cytogenetic kits and reagents in the above mentioned end users.

Major Market Developments

• In January 2014, Roche acquired Genia Technologies, Inc. (U.S.). This acquisition strengthened Roche’s Next Generation Sequencing pipeline.
• In February 2015, Roche acquired Signature Diagnostics AG (Germany).
• In January 2016, Thermo Fisher Scientific, Inc. acquired Affymetrix (U.S.). This acquisition strengthened Thermo Fisher Scientific’s leadership into bioscience business and create new market opportunities in genetic analysis.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224

Based on regions, the global molecular cytogenetics market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as increase in the aging population and increasing prevalence of cancer and genetic disorders in the region.

Key players in the molecular cytogenetics market include F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Gene Technology (U.K.), and Applied Spectral Imaging (U.S.).